Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 7 June 2024, including: BIO Notebook; ASCO roundup; data on Carvykti in community at ASCO; strong new results for tirzepatide in MASH; and orphan slowdown signals new path ahead.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More" - Scrip, 5 June, 2024.)
(Also see "ASCO Roundup: Looking For The Future Of Cancer Research" - Scrip, 5 June, 2024.)
(Also see "ASCO: Legend/J&J Explore Carvykti In Community" - Scrip, 3 June, 2024.)
(Also see "EASL: Tirzepatide Is The One To Beat In MASH" - Scrip, 5 June, 2024.)
(Also see "Orphan Drugs – Slowdown Signals New Paths Ahead" - Scrip, 4 June, 2024.)
